Virtual Sleep Conference 2021

June 10 – June 13, 2021

Posters

Please click to see the poster presentations shared at Virtual Sleep Conference 2021.

Daridorexant improves total sleep time (TST) in insomnia patients without altering the proportion of sleep stages

Daridorexant is safe and improves both sleep and daytime functioning in elderly patients with insomnia

A benefit-risk assessment of daridorexant for the treatment of insomnia using patient preference data from 2 phase 3 trials

Absence of withdrawal symptoms and rebound insomnia upon discontinuation of daridorexant in patients with insomnia

Daridorexant, a dual orexin receptor antagonist, improves age-related insomnia in rats

Daridorexant: a dual, equipotent, and insurmountable antagonist of orexin-1 and orexin-2 receptors

Effect of the dual orexin receptor antagonist daridorexant on motor function upon awakening in rats and dogs

Daridorexant improves total sleep time (TST) in insomnia patients without altering the proportion of sleep stages

Daridorexant is safe and improves both sleep and daytime functioning in elderly patients with insomnia

A benefit-risk assessment of daridorexant for the treatment of insomnia using patient preference data from 2 phase 3 trials

Absence of withdrawal symptoms and rebound insomnia upon discontinuation of daridorexant in patients with insomnia

Daridorexant, a dual orexin receptor antagonist, improves age-related insomnia in rats

Daridorexant: a dual, equipotent, and insurmountable antagonist of orexin-1 and orexin-2 receptors

Effect of the dual orexin receptor antagonist daridorexant on motor function upon awakening in rats and dogs

If you would like to request any additional information, please contact Idorsia Medical Information by completing the medical inquiry form found here.

US Consumer (e.g., patient) US Healthcare Professional